Roman M. Shapiro

Oncology
450 Brookline Avenue
Boston, MA 02115

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 50 publications

Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.

Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 30, 2026

Venetoclax-Augmented RIC Allogeneic HCT With PTCy-Based GVHD Prophylaxis and Venetoclax/Azacitidine Maintenance for Poor Risk MDS and AML.

Venetoclax-Augmented RIC Allogeneic HCT With PTCy-Based GVHD Prophylaxis and Venetoclax/Azacitidine Maintenance for Poor Risk MDS and AML.

Journal: Transplantation and cellular therapy
Published: April 28, 2026

Impact of Post-Transplant Cyclophosphamide on the Prognostic Value of HCT-CI.

Impact of Post-Transplant Cyclophosphamide on the Prognostic Value of HCT-CI.

Journal: Transplantation and cellular therapy
Published: November 22, 2025

eGFR Discordance and Its Association with Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation and Adoptive T-Cell Therapies.

eGFR Discordance and Its Association with Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation and Adoptive T-Cell Therapies.

Journal: Journal of the American Society of Nephrology : JASN
Published: November 20, 2025

Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor-risk MDS/AML.

Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor-risk MDS/AML.

Journal: Blood advances
Published: October 01, 2025

Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor risk MDS/AML.

Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor risk MDS/AML.

Journal: Blood advances
Published: October 01, 2025

Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic Transplantation.

Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic Transplantation.

Journal: Blood advances
Published: September 16, 2025

Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation.

Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation.

Journal: Blood advances
Published: September 16, 2025

No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.

No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.

Journal: Blood advances
Published: August 19, 2025

No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.

No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.

Journal: Blood advances
Published: August 19, 2025

Targeting PD-1 for HCT relapse: an immunologic knife's edge.

Targeting PD-1 for HCT relapse: an immunologic knife's edge.

Journal: Blood advances
Published: July 30, 2025

Expression of HLA-B*35 is Associated With an Increased Risk of CMV Viremia and Clinically Significant CMV Infection following PTCy-Based Hematopoietic Cell Transplantation.

Expression of HLA-B*35 is Associated With an Increased Risk of CMV Viremia and Clinically Significant CMV Infection following PTCy-Based Hematopoietic Cell Transplantation.

Journal: Transplantation and cellular therapy
Published: June 13, 2025
Showing 1-12 of 50

Last Updated: 09/26/2026